






Olliaro *Parasitol. Today* **1999**, *11*, 294 Ridley, *Nature*, **2003**, *424*, 887























Conclusions and Future Directions

Artemisinin and its more bioavailable congeners are currently the state of the art treatment of uncomplicated multidrug resistent malaria. To delay the onset of parasite resistance, caution should be exerted in using artemisinins as a first line of intervention in areas where more traditional drugs are still active

• The molecular mechanism of action against *P. falciparum* has been investigated and the role of active radical or electrophilic species generated through oxidation by iron (II) is well established. More work needs to be done to elucidate the exact source of iron used for activation (free iron, iron-heme, iron bound to cytoplasmic metalloproteines)

■ A potential target for the parasitocide activity has been identified to be the malarial PfATP6 enzyme. More proof is required to establish if PfATP6 inhibition is actually part of the killing mechanism. The sequencing of parasite genome should provide more insights into other potential artemisinin targets, and shed light on the mechanism of resistance to antimalarials

• A number of syntheses have been reported to date, involving mostly ene reactions or singlet oxygen additions to an olefin, followed by a rearrangement cascade to furnish the 1, 2, 4 trioxane ring